The levels of the leptin and adiponectin according to body mass index and their relationship with oxidative parameters;Vücut kütle indeksine göre leptin ve adiponektin seviyeleri ve bunların oksidatif parametrelerle ilişkisi

Anadolu Kardiyoloji Dergisi

Volumn 10, Issue 5, 2010, Pages 391-396

  Söylemez, Nihat ^a   Demirbaǧ, Recep ^a   Sezen, Yusuf ^a   Yildiz, Ali ^a   Akpinar, Onur ^b  

^a HARRAN UNIVERSITY   (Turkey)

^b Park Medical Hospital   (Turkey)

Author keywords

Adiponectin; Antioxidant capacity; Leptin; Obesity; Oxidative stress index

Indexed keywords

ADIPONECTIN; ANTIOXIDANT; LEPTIN;

ADULT; AGE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; NORMAL HUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; SEX RATIO; VOLUNTEER; WAIST CIRCUMFERENCE;

EID: 78049288289     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2010.134     Document Type: Article

References (35)

1. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002; 60: S1-14.
2. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 2002; 26: 1407-33.
3. Ren J. Leptin and hyperleptinemia from friend to for cardiovascular function. J Endocrinol 2004; 181: 1-10.
4. Kartal O, Inal V, Baysan O, Saǧlam K. Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients. Anadolu Kardiyol Derg 2008; 8: 342-6.
5. Bilgili S, Çelebiler AC, Doǧan A, Karaca B. Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocr Regul 2008; 42: 63-8.
6. Göksoy H, Dursunoǧlu D, Öztürk M, Rota S. The association between serum adiponectin levels and the severity of coronary artery lesions on the angiogram. Türk Kardiyol Dern Arş 2009; 37: 241-5.
7. Kolotkin RL, Meter K, Wiliams GR. Health related quality of life and obesity. Obes Rev 2001; 2: 219-29.
8. Rohner-Jeanrenaud F. A neuroendocrine reappraisal of the dual-center hypothesis: its implications for obesity and insulin resistance. Int J Obes Relat Metab Disord 1995; 19: 517-34.
9. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337: 396-407.
10. Cros CE, Halliwell B, Borish E, Pryor WA, Ames BN, Saul RL, et al. Oxygen radicals and human disease. Ann Intern Med 1987; 107: 526-45.
11. McCord JM. Human disease, free radicals, and the oxidant/ antioxidant balance. Clin Biochem 1993; 26: 351-7.
12. Demirbaǧ R, Yilmaz R, Gür M, Çelik H, Güzel S, Selek S, et al. DNA damage in metabolic syndrome and its association with antioxidative and oxidative measurements. Int J Clin Pract 2006; 60: 1187-93.
13. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol 2007; 292: H904-11.
14. Beltowski J, Wójcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170: 21-9.
15. Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 96-100.
16. Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65.
17. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277-85.
18. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-11.
19. Demirbaǧ R, Yilmaz R, Erel O, Gültekin U, Aşci D, Elbasan Z. The relationship between potency of oxidative stress and severity of dilated cardiomyopathy. Can J Cardiol 2005; 21: 851-5.
20. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
21. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin Implications fpr metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-85.
22. Uchida-Kitajima S, Yamauchi T, Takashina Y, Okada-Iwabu M, Iwabu M, Ueki K, et al. 5-Hydroxytryptamine 2A receptor signaling cascade modulates adiponectin and plasminogen activator inhibitor 1 expression in adipose tissue. FEBS Lett 2008; 582: 3037-44.
23. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein adiponectin in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
24. Stringer DM, Sellers EA, Burr LL, Taylor CG. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes 2009; 10: 269-77.
25. Amiri F. Metabolic syndrome, insulin resistance and oxidative stress: adding insights to improve cardiovascular prevention. J Hypertens 2009; 27: 1352-4.
26. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.
27. Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004; 109: 2181-5.
28. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and haematopoiesis. J Leukoc Biol 2000; 68: 437-46.
29. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005; 54: 2227-34.
30. Robertson SA, Leinninger GM, Myers MG Jr. Molecular and neural mediators of leptin action. Physiol Behav 2008; 94: 637-42.
31. Beltowski J, Jamroz-Wisniewska A, Wójcicka G, Lowicka E, Wojtak A. Renal antioxidant enzymes and glutathione redox status in leptin-induced hypertension. Mol Cell Biochem 2008; 319: 163-74.
32. Winer JC, Zern TL, Taksali SE, Dziura J, Cali AM, Wollschlager M, et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4415-23.
33. Lautamäki R, Rönnemaa T, Huupponen R, Lehtimäki T, Iozzo P, Airaksinen KE, et al. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007; 56: 881-6.
34. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009; 6: 27-35.
35. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes 2006; 55: 1840-6.